Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer

Zev A. Wainberg, MD, codirector, UCLA GI Oncology Program, and professor of medicine, UCLA Health, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus standard-of-care trastuzumab (Herceptin), ramucirumab (Cyramza), and paclitaxel in HER2-overexpressing gastric/gastroesophageal junction cancer.

News

® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastric Cancer

Gastrointestinal Cancers Symposium (ASCO GI)

ELI-22-OSD1267 - /conference/gi

Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.